InveniAI Announces Collaboration with Ono Pharmaceutical for Target Discovery Teams will work together by leveraging InveniAI's technology platform to identify, evaluate, and optimize novel targets across Ono’s diseases of interestOno will access InveniAI’s AI platform...

Glycomics Market to be Worth USD 3.1 billion by 2031 Globally, at a CAGR of 11.2 % | TMR Report Wilmington, Delaware, United States, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global glycomics market is projected to flourish at a CAGR of 11.2% from 2023 to 2031....

InveniAI's AlphaMeld Platform Debuts the Addition of ChatAlphaMeld™, A Powerful Tool Designed to Scale Target and Drug Discovery and Development Powered by GPT-4, ChatAlphaMeld enables user interaction across functional stakeholders to automate hypothesis generation and prioritization Integrated into the AlphaMeld workflow, ChatAlphaMeld is...

InveniAI and PRISM BioLab Initiate a Collaboration for the Development of Therapeutic Candidates for Treatment of Gut-Related Diseases Impacted by the Gut-Brain Axis and Inflammasome Activation Pathways Partnership with Japan-based PRISM BioLab will enable the synthesis and development of proprietary therapeutic small-molecule candidates against molecular targets identified by InveniAI’s AI platform...